校正:通过小分子抑制剂准人类B淋巴瘤中的RAB7,阻止瘤细胞生长
Maria Fernandez1, Rui Wang1, Jingwei Wang1
1Department of Microbiology, Immunology and Molecular Genetics, Joe R. & Teresa Lozano Long School of Medicine, The University of Texas at San Antonio, San Antonio, TX, United States.
Frontiers in oncology
|October 22, 2025
概括
这项研究纠正了先前发表的一篇文章的DOI. 校正确保准确引用和检索研究结果,以加强科学沟通.
科学领域:
- 在瘤学瘤学.
- 生物医学研究生物医学研究
背景情况:
- 之前的出版物需要对其数字对象标识符 (DOI) 进行更正.
- 准确的DOI对于科学文献的可追溯性和引用完整性至关重要.
研究的目的:
- 为了提供正确的DOI的文章.
- 确保研究人员能够准确地访问和引用该研究.
主要方法:
- 对该文章的DOI进行了纠正.
主要成果:
- 对该产品的正确DOI已被确定并提供.
结论:
- 这种纠正有助于正确引用和访问研究.
- 确保DOI准确性维护科学记录的完整性.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


